Developmental clinical trials: building one step at a time.
Karp
Judith E
JE
Smith
B Douglas
BD
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D017321:Clinical Trials, Phase I as Topic / Q000592:standards*; D003561:Cytarabine / Q000008:administration & dosage / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D009436:Neural Tube Defects / Q000188:drug therapy*; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology*; D012107:Research Design; D013882:Thiosemicarbazones / Q000008:administration & dosage / Q000494:pharmacology*
D000970:Antineoplastic Agents; D011725:Pyridines; D013882:Thiosemicarbazones; D003561:Cytarabine; C078157:3-aminopyridine-2-carboxaldehyde thiosemicarbazone